IP Library › Granted Patent US 11,292,766
Granted Patent B2
US 11,292,766 · App. 16/713,667 · Granted Apr 5, 2022

Substituted piperidine compound and use thereof

Inventors: Tatsuhiko Fujimoto (Kanagawa, JP); Kentaro Rikimaru (Kanagawa, JP); Koichiro Fukuda (Kanagawa, JP); Hiromichi Sugimoto (Tokyo, JP); Takahiro Matsumoto (Kanagawa, JP); Norihito Tokunaga (Kanagawa, JP); Mariko Hirozane (Kanagawa, JP)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
C07D215/44A61P25/00C07D211/24C07D211/36C07D211/56C07D401/06C07D401/12C07D401/14C07D405/06C07D405/12C07D405/14C07D409/06C07D409/12C07D413/06C07D417/06C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,292,766
App. No.
16/713,667
Granted
Apr 5, 2022
Kind
B2
Abstract

Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.

Claims (96)

1. A compound represented by the formula:

wherein

R 1 is an acyl group, or a hydrogen atom;

R 2 is an optionally substituted 3- to 6-membered saturated cyclic group; and

R 3 is an optionally substituted C 1-6 alkyl group, a mono- or di-C 1-6 alkylamino group or a C 3-6 cycloalkyl group,

or a salt thereof.

2. The compound according to claim 1 , wherein R 3 is an optionally substituted C 1-6 alkyl group or a mono- or di-C 1-6 alkylamino group, or a salt thereof.

3. The compound according to claim 1 , which is represented by the formula:

wherein R 1 , R 2 and R 3 are as defined in claim 1 , or a salt thereof.

4. The compound according to claim 1 , wherein R 1 is an acyl group, or a salt thereof.

5. The compound according to claim 1 , wherein R 2 is a C 3-6 cycloalkyl group substituted by one optionally substituted phenyl group, or a salt thereof.

6. The compound according to claim 1 , wherein R 3 is an optionally substituted C 1-6 alkyl group, or a salt thereof.

7. The compound according to claim 1 , wherein R 1 is

(1) a hydrogen atom,

(2) an optionally substituted C 1-6 alkyl-carbonyl group,

(3) an optionally substituted C 3-10 cycloalkyl-carbonyl group,

(4) an optionally substituted C 1-6 alkoxy-carbonyl group,

(5) an optionally substituted C 3-10 cycloalkyloxy-carbonyl group,

(6) an optionally substituted C 6-14 aryl-carbonyl group,

(7) an optionally substituted C 6-14 aryloxy-carbonyl group,

(8) an optionally substituted 5- to 14-membered aromatic heterocyclylcarbonyl group,

(9) an optionally substituted 3- to 14-membered non-aromatic heterocyclylcarbonyl group,

(10) an optionally substituted mono- or di-C 1-6 alkyl-carbamoyl group,

(11) an optionally substituted mono- or di-C 3-10 cycloalkyl-carbamoyl group,

(12) an optionally substituted mono- or di-C 6-14 aryl-carbamoyl group,

(13) an optionally substituted C 1-6 alkylsulfonyl group,

(14) an optionally substituted C 3-10 cycloalkylsulfonyl group,

(15) an optionally substituted C 6-14 arylsulfonyl group,

(16) an optionally substituted heterocyclyl-sulfonyl group,

(17) an optionally substituted mono- or di-C 1-6 alkyl-sulfamoyl group or

(18) an optionally substituted C 1-6 alkyl-carbonyl-carbonyl group;

R 2 is a C 3-6 cycloalkyl group or a 3- to 6-membered saturated monocyclic non-aromatic heterocyclic group, each of which is optionally substituted by 1 to 3 substituents selected from

(1) deuterium,

(2) a halogen atom,

(3) a hydroxy group,

(4) an optionally substituted C 1-6 alkyl group,

(5) a C 3-10 cycloalkyl group,

(6) an optionally substituted C 1-6 alkoxy group,

(7) an optionally substituted C 6-14 aryl group,

(8) a C 6-14 aryloxy group,

(9) a tri-C 1-6 alkylsilyloxy group,

(10) an optionally substituted 5- to 14-membered aromatic heterocyclic group and

(11) an optionally substituted C 6-14 aryl-carbonyl group; and

R 3 is a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a C 6-14 aryl group, or a mono- or di-C 1-6 alkylamino group, or a salt thereof.

8. The compound according to claim 1 , wherein R 1 is

(1) a hydrogen atom,

(2) a C 1-6 alkyl-carbonyl group optionally substituted by 1 to 7 substituents selected from (i) a halogen atom, (ii) a cyano group, (iii) a hydroxy group, (iv) a C 3-10 cycloalkyl group, (v) a C 1-6 alkoxy group, (vi) a C 6-14 aryl group, (vii) a C 6-14 aryloxy group, (viii) a pyrazolyl group, a thiazolyl group, a pyrimidinyl group or a pyridazinyl group, each of which is optionally substituted by an oxo group, (ix) a pyrazolyloxy group optionally substituted by 1 to 3 C 1-6 alkyl groups, (x) a C 1-6 alkyl-carbonyl group, (xi) a C 1-6 alkoxy-carbonyl group, (xii) a C 1-6 alkyl-carbonyloxy group, (xiii) a C 1-6 alkylsulfonyl group, (xiv) a mono- or di-C 1-6 alkylamino group, (xv) a C 1-6 alkyl-carbonylamino group and (xvi) a (C 1-6 alkyl)(C 1-6 alkyl-carbonyl)amino group,

(3) a C 3-10 cycloalkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from a halogen atom, a cyano group, a hydroxy group, an oxo group and a C 1-6 alkyl group,

(4) a C 1-6 alkoxy-carbonyl group optionally substituted by 1 to 6 substituents selected from deuterium, a halogen atom and a C 6-14 aryl group,

(5) a C 3-10 cycloalkyloxy-carbonyl group optionally substituted by 1 to 3 substituents selected from a C 1-6 alkyl group,

(6) a C 6-14 aryl-carbonyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a C 6-14 aryl group,

(7) a C 6-14 aryloxy-carbonyl group,

(8) a furylcarbonyl group, a thienylcarbonyl group, a pyrazolylcarbonyl group, an isoxazolylcarbonyl group or a pyridylcarbonyl group, each of which is optionally substituted by 1 to 3 substituents selected from a C 1-6 alkyl group,

(9) an azetidinylcarbonyl group, an oxetanylcarbonyl group, a pyrrolidinylcarbonyl group, a tetrahydrofuranylcarbonyl group, a tetrahydropyranylcarbonyl group or a morpholinylcarbonyl group, each of which is optionally substituted by 1 to 3 substituents selected from an oxo group, a C 1-6 alkyl-carbonyl group, a C 1-6 alkoxy-carbonyl group and a C 1-6 alkylsulfonyl group,

(10) a mono- or di-C 1-6 alkyl-carbamoyl group optionally substituted by 1 to 3 substituents selected from a halogen atom, a cyano group, a hydroxy group and a C 1-6 alkoxy group,

(11) a mono- or di-C 3-10 cycloalkyl-carbamoyl group,

(12) a mono- or di-C 6-14 aryl-carbamoyl group,

(13) a C 1-6 alkylsulfonyl group,

(14) a C 3-10 cycloalkylsulfonyl group,

(15) a C 6-14 arylsulfonyl group optionally substituted by 1 to 3 halogen atoms,

(16) a thienylsulfonyl group, a pyrazolylsulfonyl group, an imidazolylsulfonyl group, a pyridylsulfonyl group or a dihydrochromenylsulfonyl group, each of which is optionally substituted by 1 to 3 substituents selected from a C 1-6 alkyl group,

(17) a mono- or di-C 1-6 alkyl-sulfamoyl group or

(18) a C 1-6 alkyl-carbonyl-carbonyl group;

R 2 is a C 3-6 cycloalkyl group, a pyrrolidinyl group, a piperidinyl group or a dioxanyl group, each of which is optionally substituted by 1 to 3 substituents selected from

(1) deuterium,

(2) a halogen atom,

(3) a hydroxy group,

(4) a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a C 6-14 aryl group,

(5) a C 3-10 cycloalkyl group,

(6) a C 1-6 alkoxy group optionally substituted by a C 3-10 cycloalkyl group,

(7) a C 6-14 aryl group optionally substituted by 1 to 3 substituents selected from a halogen atom, a cyano group, a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms, a C 1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms and a hydroxy group,

(8) a C 6-14 aryloxy group,

(9) a tri-C 1-6 alkylsilyloxy group,

(10) a pyrazolyl group, a thiazolyl group, a pyridyl group, a pyrimidinyl group, a quinazolinyl group, a benzothiazolyl group or an isoquinolinyl group, each of which is optionally substituted by 1 to 3 substituents selected from a halogen atom, a C 1-6 alkyl group and a C 1-6 alkoxy group, and

(11) a C 6-14 aryl-carbonyl group; and

R 3 is a C 1-6 alkyl group, or a mono- or di-C 1-6 alkylamino group, or a salt thereof.

9. The compound according to claim 1 , wherein R 1 is

(1) a hydrogen atom,

(2) a C 1-6 alkyl-carbonyl group optionally substituted by a hydroxy group,

(3) a cyclopropanecarbonyl group,

(4) a C 1-6 alkoxy-carbonyl group or

(5) a mono- or di-C 1-6 alkyl-carbamoyl group;

R 2 is

(A) a cyclohexyl group optionally substituted by 1 to 3 substituents selected from

(1) a C 1-6 alkyl group and

(2) a phenyl group optionally substituted by 1 to 3 substituents selected from a halogen atom, a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms and a C 1-6 alkoxy group or

(B) a piperidinyl group optionally substituted by 1 to 3 pyrimidinyl groups; and

R 3 is a C 1-6 alkyl group or a di-C 1-6 alkylamino group, or a salt thereof.

10. The compound according to claim 1 , wherein R 1 is

(1) a C 1-6 alkyl-carbonyl group optionally substituted by a hydroxy group,

(2) a C 1-6 alkoxy-carbonyl group or

(3) a mono- or di-C 1-6 alkyl-carbamoyl group;

R 2 is a cyclohexyl group optionally substituted by 1 to 3 substituents selected from

(1) a C 1-6 alkyl group and

(2) a phenyl group optionally substituted by 1 to 3 halogen atoms; and

R 3 is a C 1-6 alkyl group, or a salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 25, 2022
From: FUJIMOTO, TATSUHIKO; RIKIMARU, KENTARO; FUKUDA, KOICHIRO; SUGIMOTO, HIROMICHI; MATSUMOTO, TAKAHIRO; TOKUNAGA, NORIHITO; HIROZANE, MARIKO
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 058764/0058 →
Priority Claims (1)
JP 2016-019834 · Feb 4, 2016 · national
Continuity (2)
Division 16075240
Related Publication 20200115399A1 · Apr 16, 2020
Cited By (3)
US 12,281,073 US 12,534,471 US 12,594,269